Published in Cell Rep on March 03, 2015
Functions of dendritic-cell-bound IgE in allergy. Mol Immunol (2015) 0.81
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper. Allergy (2016) 0.76
Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Oncoimmunology (2016) 0.76
Eosinophilic esophagitis: published evidences for disease subtypes, indications for patient subpopulations, and how to translate patient observations to murine experimental models. World Allergy Organ J (2016) 0.76
Are Mast Cells MASTers in Cancer? Front Immunol (2017) 0.75
CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 7.46
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med (2010) 3.43
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol (2008) 3.08
Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity (2013) 1.88
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res (2013) 1.87
The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol (2014) 1.75
A beneficial role for immunoglobulin E in host defense against honeybee venom. Immunity (2013) 1.71
Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape. Immunity (2005) 1.64
AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy (2008) 1.59
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2011) 1.44
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med (2013) 1.40
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res (2009) 1.26
Ontogeny and functional specialization of dendritic cells in human and mouse. Adv Immunol (2013) 1.15
Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity (2013) 1.07
Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother (2011) 1.03
The ins-and-outs of endosomal antigens for cross-presentation. Curr Opin Immunol (2013) 1.03
Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy (2013) 1.01
Antigen cross-presentation of immune complexes. Front Immunol (2014) 0.99
Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol (2008) 0.97
Cross-presentation: how to get there - or how to get the ER. Front Immunol (2012) 0.95
Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann N Y Acad Sci (2005) 0.90
Soluble IgE receptors--elements of the IgE network. Immunol Lett (2011) 0.89
IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol (2008) 0.89
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer (2013) 0.84
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother (2011) 0.82
Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol (2012) 0.82
Functions of dendritic-cell-bound IgE in allergy. Mol Immunol (2015) 0.81